The clinical landscape of managing patients with CKD
ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.
Video navigation menu
- How do SGLT2 inhibitors work? 00:43
- Hemodynamic effects of SGLT2 inhibitors in animals and human 01:20
- Effects of SGLT2-i in non-diabetic kidney disease 08:24
- Future trials 10:26
This lecture by prof. David Cherney was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"
Prof. David Cherney - Associate Professor, Department of Medicine, University of Toronto, ON, Canada
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
Share this page with your colleagues and friends: